Plasmid DNA Manufacturing Patents: Mapping the Leaders and the Open Claim Space
Concentrated at the top. The top 5 assignees hold 158 of 519 records in scope (30.4%), and the top 10 hold 46.8% — a field where a handful of filers set the terms for lysis and purification claims. Filings rose to a peak of 24 records in 2022, then fell to 6 by 2024 — a 54% drop from the 2021 figure of 13. Because 2025 and 2026 publications are still arriving, this should be read as a real mid-decade cooling through the last complete year, not as an ongoing collapse.
- 1CENTELION SAS49
- 2FIT BIOTECH OY PLC46
- 3BOEHRINGER INGELHEIM RCV GMBH & CO KG23
- 4MERCK & CO INC20
- 5AVENTIS PHARMA SA20
See the full plasmid dna manufacturing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on plasmid DNA manufacturing patents
Who holds the most patents in plasmid DNA manufacturing?
The dataset's assignee ranking shows a single leader with 49 of the 519 records in scope, well ahead of the fifth-place assignee at 20 and the tenth-place assignee at 15. The top 5 assignees combined account for 30.4% of all records, and the top 10 for 46.8%, meaning that even the most active filers leave more than half the field to a long tail of smaller players. Anyone assessing competitive position should look at both the leader's specific claim scope and the breadth of the remaining tail, since consolidation at the very top does not mean the whole field is locked up.
Is patent filing in plasmid DNA manufacturing growing or slowing?
Filings peaked at 24 records in 2022 and fell to 6 by 2024, a 54% drop over that three-year span. That decline should be read carefully: publication typically lags actual filing by about 18 months, so 2025 and 2026 figures are still incomplete and will rise as more applications publish. The honest read is a cooling from a mid-decade peak through the last complete year, not a confirmed long-term slowdown.
What patent classes cover plasmid DNA manufacturing technology?
The dominant class is C12N, covering microorganisms and genetic engineering, present in 85.0% of the 519 records — reflecting how much of this field's patenting sits in host strain and vector biology. A61K medicinal preparation claims follow at 32.0%, with nucleic acid chemistry (C07H, 16.4%) and enzymatic or DNA measurement methods (C12Q, 16.2%) forming a smaller second tier. Because a single record can carry multiple IPC codes, these percentages add up to more than 100% and should not be treated as mutually exclusive categories.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Plasmid DNA Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.